Factors that influence adherence and strategies to maintain adherence to injected therapies for patients with multiple sclerosis

Journal of Neuroscience Nursing

Volumn 42, Issue SUPPL.5, 2010, Pages

  Saunders, Carol ^a   Caon, Christina ^b   Smrtka, Jennifer ^a   Shoemaker, Jennifer ^a  

^a School of Medicine ^*

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT;

ARTICLE; DEPRESSION; FAMILY; HUMAN; LIFESTYLE; MORALITY; MULTIPLE SCLEROSIS; NURSE ATTITUDE; NURSE PATIENT RELATIONSHIP; NURSING; PATIENT COMPLIANCE; PATIENT EDUCATION; PSYCHOLOGICAL ASPECT; RELIGION; RISK FACTOR; SELF CONCEPT; SOCIAL SUPPORT; SUBCUTANEOUS DRUG ADMINISTRATION; TRUST;

ANTIRHEUMATIC AGENTS; DEPRESSION; FAMILY; HUMANS; INJECTIONS, SUBCUTANEOUS; LIFE STYLE; MEDICATION ADHERENCE; MORALE; MULTIPLE SCLEROSIS; NURSE'S ROLE; NURSE-PATIENT RELATIONS; PATIENT EDUCATION AS TOPIC; RELIGION AND PSYCHOLOGY; RISK FACTORS; SELF EFFICACY; SOCIAL SUPPORT; TRUST;

EID: 78651446530     PISSN: 08880395     EISSN: None     Source Type: Journal    
DOI: 10.1097/JNN.0b013e3181ee122b     Document Type: Article

References (27)

1. Avonex® (interferon beta-1a) [Package insert]. (2008). Cambridge, MA: Biogen Idec, Inc.
2. Baum, K., O'Leary, C., Coret Ferrer, F., Klimova, E., Prochazkova, L., & Bugge, J. (2007). Comparison of injection site pain and injection site reactions in relapsingremitting multiple sclerosis patients treated with interferon beta-1a or 1b. Multiple Sclerosis, 13, 1153-1160.
3. BetaseronA (interferon beta-1b) [Package insert]. (2008). Montville, NJ: Bayer Healthcare Pharmaceuticals.
4. Chwastiak, L. A., & Ehde, D. M. (2007). Psychiatric issues in multiple sclerosis. Psychiatric Clinics of North America, 30, 803-817.
5. Copaxone® (glatiramer acetate) [Package insert]. (2009). Kansas City, MO: Teva Neuroscience, Inc.
6. Cox, D., & Stone, J. (2006). Managing self-injection difficulties in patients with relapsing-remitting multiple sclerosis. Journal of Neuroscience Nursing, 38, 167-171.
7. Extavia® (interferon beta-1b) [Package insert]. (2009). East Hanover, NJ: Novartis Pharmaceuticals Corporation.
8. Fraser, C., Morgante, L., Hadjimichael, O., & Vollmer, T. (2004). A prospective study of adherence to glatiramer acetate in individuals with multiple sclerosis. Journal of Neuroscience Nursing, 36, 120-129.
9. Hall, M. A., Camacho, F., Dugan, E., & Balkrishnan, R. (2002). Trust in the medical profession: Conceptual and measurement issues. Health Services Research, 37, 1419-1439.
10. Hashimoto, S., Ball, N. J., & Tremlett, H. (2009). Progressive lipoatrophy after cessation of glatiramer acetate injections: A case report. Multiple Sclerosis, 15, 521-522.
11. Isaksson, A. K., & Ahlstrom, G. (2008). Managing chronic sorrow: Experiences of patients with multiple sclerosis. Journal of Neuroscience Nursing, 40, 180-191.
12. Kalia, L. V., & O'Connor, P. W. (2005). Severity of chronic pain and its relationship to quality of life in multiple sclerosis. Multiple Sclerosis, 11, 322-327.
13. Lando, J., Williams, S. M., Williams, B., & Sturgis, S. (2006). A logic model for the integration of mental health into chronic disease prevention and health promotion. Preventing Chronic Disease, 3, A61.
14. Morgante L. (2000). Hope in multiple sclerosis: A nursing perspective. International Journal of MS Care, 2, 1-8.
15. Mohr, D. C., Boudewyn, A. C., Likosky, W., Levine, E., & Goodkin, D. E. (2001). Injectable medication for the treatment of multiple sclerosis: The influence of self-efficacy expectations and injection anxiety on adherence and ability to self-inject. Annals of Behavioral Medicine, 23, 125-132.
16. Nakamura, Y., Kawachi, Y., Furuta, J., & Otsuka, F. (2008). Severe local skin reactions to interferon beta-1b in multiple sclerosis-improvement by deep subcutaneous injection. European Journal of Dermatology, 18, 579-582.
17. Namey, M. A. (2007). Promoting adherence to complex protocols. In J. Halper (Ed.), Advanced concepts in multiple sclerosis nursing care (2nd ed., pp. 91-100). New York: Demos Medical Publishing.
18. Novantrone® (mitoxantrone) [Package insert]. (2008). Rockland, MA: EMD Serono, Inc.
19. O'Sullivan, S. S., Cronin, E. M., Sweeney, B. J., Bourke, J. F., & Fitzgibbon, J. (2006). Panniculitis and lipoatrophy after subcutaneous injection of interferon beta-1b in a patient with multiple sclerosis. Journal of Neurology, Neurosurgery, and Psychiatry, 77, 1382-1383.
20. Rebif® (interferon beta-1a) [Package insert]. (2009). Rockland, MA: EMD Serono, Inc.
21. Rothwell, P. M., McDowell, Z., Wong, C. K., & Dorman, P. J. (1997). Doctors and patients don't agree: Cross sectional study of patients' and doctors' perceptions and assessments of disability in multiple sclerosis. British Medical Journal, 314, 1580-1583.
22. Shenolikar, R. A., Balkrishnan, R., & Hall, M. A. (2004). How patient-physician encounters in critical medical situations affect trust: Results of a national survey. BMC Health Services Research, 4, 24.
23. Thom DH, & Stanford Trust Study Physicians. (2001). Physician behaviors that predict patient trust. Journal of Family Practice, 50, 323-328.
24. Trachtenberg, F., Dugan, E., & Hall, M. A. (2005). How patients' trust relates to their involvement in medical care. Journal of Family Practice, 54, 344-352.
25. Treadaway, K., Cutter, G., Salter, A., Lynch, S., Simsarian, J., Corboy, J., et al. (2009). Factors that influence adherence with disease-modifying therapy in MS. Journal of Neurology, 256, 568-576.
26. Tysabri® (natalizumab) [Package insert]. (2008). Cambridge, MA: Biogen Idec, Inc.
27. White, C. P., White, M., & Russell, C. S. (2007). Multiple sclerosis patients talking with healthcare providers about emotions. Journal of Neuroscience Nursing, 39, 89-101.